

# GLOBAL WHOLEHEALTH PARTNERS CORP

## **FORM 8-K** (Current report filing)

Filed 05/14/21 for the Period Ending 01/12/21

Address	1402 N EL CAMINO REAL SAN CLEMENTE, CA, 92672
Telephone	(714) 392-4112
CIK	0001598308
Symbol	GWHP
SIC Code	2835 - In Vitro and In Vivo Diagnostic Substances
Industry	Healthcare Facilities & Services
Sector	Healthcare
Fiscal Year	06/30

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 12, 2021

**GLOBAL WHOLEHEALTH PARTNERS CORPORATION**  
(Exact name of registrant as specified in its charter)

Nevada  
(State or other jurisdiction  
of incorporation)

000-56035  
(Commission File Number)

46-2316220  
(IRS Employer  
Identification No.)

1402 N. El Camino Real  
San Clemente, CA  
(Address of Principal Executive Offices)

92672  
(Zip Code)

Registrant's telephone number, including area code (714) 392-9752

N/A  
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Section 1 - Registrant's Business and Operations**

**Item 1.01 Entry into a Material Definitive Agreement.**

On May 12, 2021, Global Wholehealth Partners Corporation (the "Company") executed an Agreement with Dr. AnhDao Vu Le ("Dr. Le") dated January 12, 2021. The delay in executing the Agreement was a direct result of the COVID 19 pandemic. Under the terms of the Agreement, the Company has engaged Dr. Le to serve as medical director of the CLIA labs. This Agreement will allow the Company to open up a CLIA WAIVED LAB and do mobile COVID 19 testing and other CLIA WAIVED tests. The foregoing description of the Agreement does not purport to be completed and is qualified in its entirety by reference to the Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

**Section 9 – Financial Statement and Exhibits**

**Item 9.01 Financial Statements and Exhibits.**

<u>Exhibit No.</u>	<u>Document</u>	<u>Location</u>
<a href="#">10.1</a>	Agreement between Global WholeHealth Partners Corp and Dr. AnhDao Vu Le	Filed Herewith

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**GLOBAL WHOLEHEALTH PARTNERS CORPORATION**  
(Registrant)

Date: May 14, 2021

By: /s/ Charles Strongo  
Charles Strongo  
Chief Executive Officer



January 12, 2021

### Agreement between Global WholeHealth Partners Corp and Dr. Anh Dao Vu Le

This agreement is hereby between Global WholeHealth Partners Corp and Dr. Le where Global wishes to engage Dr. Le to work with Global as the medical director for the mobile CLIA LABS, and where Dr. Le wishes to be the medical director for the CLIA labs

**Terms:**

The mobile labs will test people for CoVID19 Antibody and CoVID19 Antigen tests and will charge people from \$25 for antibody to \$35 per test Antigen.

Global will supply the Antibody tests for \$7.50 and the Antigen tests for \$17.00 to the lab. Dr. Le will receive 10% of the gross sales as a compensation for being the medical director of the CLIA LAB.

If Dr. Le wishes to partners with Global, he has an opportunity to receive 30% of the gross sales from the mobile CLIA lab with an investment of \$150,000 which will assist the company in starting the project faster.

The parties agree to the terms above. Dr. Le will decide which terms he decides by indicating here:

\* No Investment ADVL Investment \_\_\_\_\_ +

Dr. Anh Dao Vu Le



Medical License A81117

Global WholeHealth Partners Corp

By:

Charles Stango



14000 Admin Trail  
C 2013, 892672  
order@gwhp-gpe.com  
order@gwhpcorp.com  
(949) 757-4152  
gwhpcorp.com

